Related Experiment Video

Updated: Aug 23, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Therapy of hepatitis C in HIV-coinfection

J K Rockstroh1, M Vogel

  • 1Medizinische Universitätsklinik I, Sigmund-Freud-Strasse 25, D-53105 Bonn, Germany. rockstroh@uni-bonn.de

European Journal of Medical Research
|July 20, 2004
PubMed

Insights

Approximately one-third of HIV patients have hepatitis C coinfection, leading to accelerated liver disease. Effective treatments are improving outcomes, but careful management is crucial due to potential drug toxicities.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Immunology

Background:

  • Hepatitis C virus (HCV) coinfection affects one-third of European and American HIV patients.
  • HIV accelerates HCV liver disease, increasing cirrhosis rates fivefold in coinfected individuals.
  • HIV-associated immune deficiency progression exacerbates liver damage in coinfected patients.

Purpose of the Study:

  • To review current treatment strategies for HIV/HCV coinfection.
  • To highlight the impact of highly active antiretroviral therapy (HAART) on HCV outcomes.
  • To emphasize the need for management guidelines considering treatment-related hepatotoxicity.

Main Methods:

  • Review of cohort analyses and clinical data on HIV/HCV coinfection.
  • Analysis of sustained virological response rates with combination therapy.
  • Evaluation of HAART's impact on hepatitis C progression and mortality.

Main Results:

  • Pegylated interferon and ribavirin therapy achieves up to 40% sustained virological response in coinfected patients.
  • HAART improves the course of hepatitis C and reduces liver disease mortality.
  • Current antiretroviral regimens can increase hepatotoxicity in coinfected patients.

Conclusions:

  • Combination therapy and HAART offer improved outcomes for HIV/HCV coinfected patients.
  • Management of hepatitis C coinfection in HIV requires careful consideration of hepatotoxicity.
  • Development of specific treatment strategies and guidelines is essential for this population.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...